Among the potential nonviral vectors for hunian gene therapy are DNA-liposome complexes. In a recent clinical study, this delivery system has been utilized. In this report, a novel cationic lipid, dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE), has been substituted into the DNA-liposome complex with dioleoyl phosphatidylethanolamine (DOPE), which both improves transfection efficiencies and allows increased doses of DNA to be delivered in vivo. The safety and toxicity of this DNA-liposome complex has been evaluated in two species, mice and pigs. The efficacy of DMRIE/DOPE in inducing an antitumor response in mice after transfer ofa foreign MHC has been confirmed. No abnormalities were detected after administration of up to 1,000-fold higher concentrations of DNA and lipid than could be tolerated in vivo previously. Examination ofserum biochemical enzymes, pathologic examination of tissue, and analysis of cardiac function in mice and pigs revealed no toxicities related to this treatment. This improved cationic lipid formulation is well-tolerated in vivo and could therefore allow higher dose administration and potentially greater efficiency of gene transfer for gene therapy.
INTRODUCTION
Although several viral vectors have been widely applied to the treatment of human disease, the development of nonviral vectors is still in their infancy. In this report, a novel cationic lipid, DMRIE/DOPE, has been incorporated into the DNA-liposome formulation that improves transfection efficiencies and allows up to 1,000-fold higher concentrations of DNA to be administered in vivo. In this paper, the safety and toxicity of this formulation is described in two species, mice and pigs, suggesting that it may prove useful for human gene therapy.
ALTHOUGH SEVERAL VIRAL DELIVERY SYSTEMS are available for human gene therapy, nonviral vectors are not as well utilized for gene transfer in vivo. We have previously employed a nonviral vector in a human gene therapy protocol in an attempt to stimulate tumor immunity by expression of a foreign histocomparibility antigen in patients with melanoma (G.J. Nabel era/., 1992a,b, 1993). Although several features of such nonviral vectors are attractive for direct gene transfer in vivo, a limitation of this system is the relative efficiency of gene transfer. Although the ability to deliver recombinant genes with Departments of 'Internal Medicine and ^Biological Chemistry, ^Pediatrics, and "Pathology, and 'Howard Hughes Medical Insdtute, University of Michigan Medical Center, Ann Arbor, MI 48109-0650.
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DNA-liposome complexes and to modify biologic effects in vivo has been established (E.G. Nabel et al., , 1993a Plautz et al., 1993) , the ability to transduce larger numbers of cells could greatly expand its utility. There are several potential advantages of DNA-liposome complexes as a nonviral delivery system. Because the DNA is not directly derived from a replication competent virus, its expression is limited. It is unlikely to integrate or propagate in animal cells, thus minimizing concems related to public health and vector safety. In addition, cationic lipids have been welltolerated in vivo (E.G. Stewart et al., 1992) . Based on a variety of animal models (E.G. Nabel et al., ,b, 1993a Stewart et al., 1992) and clinical studies (G.J. Nabel et al., , 1993 in progress, applicarions of this technology are likely to expand in the future. Finally, the ability to deliver recombinant genes using catheter-based delivery has further allowed for site-specific gene expression in vivo.
Despite the advantages of this technique, some limitarions of the present technology remain. Among them has been the relatively low concentration of DNA-liposome complexes that are employed. In previous studies, higher absolute concentrations of DNA-liposome complexes led to aggregation and toxicity following intravenous injection in mice in vivo (Stewart et al., 1992) . A new formulation (Feigner et al., 1993 ) is characterized in this report. This DNA-liposome formulation displays a modestly higher transfection efficiency in vitro. More importantly, it does not show toxicity at higher absolute concentrations of DNA and lipid. In this report, we characterize the in vivo toxicities of this formulation in mice and pigs. We find minimal toxicity at lipid and DNA concentrations up to 1000-fold higher than those used previously. Based on these results, this DNA-liposome formulation may be an appropriate delivery vehicle for gene transfer in humans.
MATERIALS AND METHODS

Plasmids and transfections
A plasmid containing the HLA-B7 gene (G.J. Nabel et al., , 1993 under the control of the Rous sarcoma virus long terminal repeat (RSV-LTR) was used for transfection of different primary and transformed cell lines and for in vivo toxicity analysis. This plasmid was approved for use in our previous human clinical protocol (G.J. Nabel etal., 1992a Nabel etal., , 1993 . Cells were transfected with dimethylaminoethane-carbamoyl cholesterol (DC-Chol)/dioleoyl phosphatidylethanolamine (DOPE) in an optimal concentration (15 nmol DC-Chol/DOPE; I p,g DNA in 0.7 ml) as previously described (Gao and Huang, I99I; Stewart et al., 1992) . The newer DNA-liposome formulation was prepared by incubation of DNA (5 p,g) and dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE)/DOPE (15 nmol) in a final volume of 1 ml in lactated Ringer's solution for in vitro transfections.
Animal studies
Adult female mice (strain BALB/c) and domestic pigs were used for all in vivo experiments. Experiments in mice were performed to evaluate escalating doses of DNA and liposomes injected intravenously. Intravenous injections were carried out via the tail vein using a 21-gauge needle. In mice, for intravenous injections, DNA (0.5-50 p,g) and DMRIE/DOPE (1.5-150 nmol) were mixed in a final volume of 0.1 ml immediately prior to injection. Blood was collected from the tail vein before intravenous injection ofthe DNA-liposomes and 10 days later. At about 2 weeks following injection, liver, kidney, lung, heart, and brain were removed for histologic analysis and extracted for polymerase chain reaction (PCR) DNA amplification using primers and conditions described previously (G.J. Nabel et al., 1993) in one group of mice (n = 5). In a second group, injections were repeated at 2-week intervals for a total of three times. Blood was collected before the first injections and 6 weeks later, at which time organs were removed and analyzed by histology and PCR.
Additional toxicity studies were performed in 12 pigs to evaluate the local and systemic effects of three doses of DNA and liposomes when delivered by a catheter to a local peripheral artery segment. Intra-arterial gene transfer was performed using a double balloon catheter (USCI, Bard, Inc., Billerica, MA) with methods previously described (Nabel et al., 1990) . In these experiments, the plasmid containing the HLA-B7 gene was mixed with DMRIE/DOPE in three concentrations: HLA-B7 DNA 0.5 p,g and DMRIE/DOPE 1.5 nmol (2 pigs); HLA-B7 DNA 5 p,g and DMRIE/DOPE 15 nmol (4 pigs); and HLA-B7 DNA 50 p,g and DMRIE/DOPE 150 nmol (6 pigs). The animals were sacrificed at 17-21 days. The following evaluations were performed. Tissue analysis for PCR and histology were done 17-21 days following gene transfer to determine the effectiveness of gene transfer and the effects of gene expression on tissues. Serum chemistries were measured before gene transfer and 17 days later to examine effects of DNA and DMRIE/DOPE liposomes on liver, renal, and cardiac function.
The PCR reactions were performed as previously described (G.J. Nabel et al., 1993) with a 2-min annealing and extension at 72°C and 1 min of dissociation of 94°C. Plasmid DNA was used as positive control (1 ng). The sensitivity of detection has been estimated to be between 1 copy per 10^-10^ genomes (Stewart et al., 1929) . Serum samples were stored frozen at -20°C for measurement of tissue-specific enzymes and routine biochemical parameters.
Studies of cardiac toxicity
The effects of intravenous DNA-liposome complexes on cardiac tissue were assessed by measurement of total creatine phosphokinase (CPK), CPK isoenzymes, and electrocardiography (EKG) on 15 mice prior to and following DNA-liposome injection. Total CPK values were determined prior to injection. Mice received HLA-B7 DNA-liposome conjugates prepared as described above (0.1 cc) injected into the tail vein. CPK measurements were made on serum samples obtained 16 hr after injection. Control mice were injected with 0.1 cc of saline, and total CPK was measured at 16 hr.
As an independent parameter to evaluate cardiac function, EKG measurements were performed prior to DNA-liposome complex or saline injection, during injection, and I and 5 min following injection. The mice were anesthetized and surface lead electrodes were attached to the four limbs using alcohol.
Surface lead I or II was monitored at a chart speed of 50 mm/sec. After the baseline EKG was obtained, continuous measurements were made during injection. and standard errors of the mean (SEM) prior to and following gene transfer were compared using a two-tailed paired Mest. Results were considered statistically significant if p ^ 0.05.
Direct arterial gene transfer in vivo
Direct arterial transfection was performed in 12 pigs using methods as previously described in peripheral iliofemoral arteries using a catheter (E.G. Nabel et al., 1990 . In this study, the expression ofthe human recombinant gene was analyzed up to 17 days following direct gene transfer in pigs. Genomic DNA was prepared from transfected and nontransfected arteries, ovary or testes, heart, lung, liver, spleen, kidney, and skeletal muscle by standard proteinase K digestion and phenol and chloroform extraction conditions. Oligonucleotide primers were synthesized to generate the 525-bp fragment as described above.
Analysis of organ toxicity
Organ specimens, including transfected and nontransfected artery, ovary or testes, brain, heart, lung, liver, spleen, kidney, and muscle were obtained when the animals were sacrificed, fixed in formalin, embedded in paraffin, and stained in hematoxylin and eosin. Representative sections were examined by an experienced pathologist (D.G.) in a blinded fashion.
Serum from mice or pigs was obtained prior to sacrifice, frozen at -20°C, and biochemical analyses were performed (Roche Biomedical Laboratories, Dublin, OH). Mean values
RESULTS
Comparison of transfection efficiencies of DMRIEIDOPE and DC-ChollDOPE in vitro
To compare the efficacy of DMRIE/DOPE to the DC-Chol/ DOPE, a variety of cell lines were transfected in vitro. Among the cell lines, the DMRIE/DOPE formulation showed an improved transfection efficiency ranging from two-to seven-fold, depending on the lines that were examined (Fig. 1) . In general, the relative improvement with DMRIE/DOPE was most effective in cell lines that were difficult to transfect with both cationic lipids, e.g., MCA 205 fibrosarcoma. It is also important to note that a higher concentration of plasmid DNA was used with DMRIE/DOPE (5 jjig) than DC-Chol/DOPE (1 p,g) because this higher concentration of plasmid was toxic to cells in vitro with DC-Chol/DOPE (Stewart et al., 1992) . Thus, DMRIE/DOPE is not necessarily more potent than DC-Chol/ DOPE, but its relative lack of toxicity allows larger quantities of DNA to be used in vitro and in vivo.
In DOPE formulation, a marked antitumor effect was obtained after introduction of a foreign MHC gene (H-2K'') that was not seen with DC-Chol (Fig. 2) .
Distribution of DNA-liposome complexes after intravenous and intra-arterial administration
To characterize the distribution of DNA-liposome complexes after injection in vivo, the complexes were prepared and injected into the tail vein of BALB/c mice. The RSV HLA-B7 plasmid used for the human gene therapy protocol was utilized for these studies. Increasing concentrations of DNA-liposome complexes were tested in three groups. The lowest dose represented a lO-fold higher initial dose than for the human gene therapy trial (0.5 p.g plasmid DNA; 1.5 nmol DMRIE/DOPE) based on a weight/body surface area ratio. The highest dose was 1,000-fold greater. PCR analysis of DNA from major murine organs, including heart, lung, brain, liver, and kidney, showed that the injected DNA was detected in multiple organs, including the lung and heart, with these mice after 10 days (Table  IA) . However, the presence of DNA in these organs was not associated with organ pathology (see below). The localization of DNA-liposome complexes in different tissues has been described previously (Stewart et al., 1992) , where it was found transiently in cells ofthe reticuloendothelial cell system. Localized gene transfer to arterial segments was performed in 12 pigs at three doses, HLA-B7 DNA 0. Organ toxicity lymphoid aggregates in the lung or liver were seen in control animals that did not receive DNA-liposome treatments in preTo determine whether the introduction of DNA-liposome ^^^^^ ^^^^^^ ^^^ ^^^^, ^, ^, j^^ja; Stewart et al., 1992) . complexes in vivo produced toxicity to major organ systems, si^ji^^iy^ "" pathological abnonnalities were detected after several semm biochemical parameters were evaluated either ^^^^^ treatments with DNA-liposome complexes in mice (data after a single injection or after three separate injections made at ^^^ ^j^^^^, analogous to the protocol used m our human clini-2-week intervals in mice and pigs. The previous studies regard-^^, ^^.^^ ^^ j ^^^g, ^, ^^ ,992a, 1993). In addition, toxicity ing the long-term toxicity and immunologic consequences of ^^^^.^^ ^^^^ performed in pigs following direct arterial gene expression of a foreign MHC gene have been previously re-^^^^^^^^ ^^^^^^ pathology studies demonstrated that the adminported with no adverse effects noted (E.G. Nabel etal.,\992a). .^^^^^^.^^ ^^DNA-liposome complexes intra-arterially was wellAnalysis of serum enzymes and protein from liver, kidney, j^j^^^j^j .^ ^.^^ ^-^.^ ^^ ^^^^^^^ responses detected biochemibone, and pancreas revealed no significant changes 10 days ^^"y (.j,^,^,^ ^^ ^^ -^^ ^j^^^^^ ^j^^^^ g^ after a single injection (Table 2 ) or 14 days after three treatments administered at 2-week intervals (Table 3) . Similar analyses were performed in pigs that received arterial gene transfer Cardiac toxicity with DNA-liposome complexes, and no biochemical abnormalities were observed (Table 4 ). Pathology analysis of tissues As in previous studies, plasmid DNA was detected after from these animals showed occasional incidental changes unre-intravenous injection in the heart by PCR analysis. Therefore, lated to the introduction of DNA-liposome complexes (Table we examined whether this formulation caused significant acute 5). The incidental findings, including occasional peribronchial or chronic toxicity from this treatment. We first evaluated the potential for acute effects of this treatment by examining the electrocardiogram before, during, and after injection on DMRIE/DOPE plasmid complexes. As observed with DC-Chol liposomes, this analysis revealed no abnormalities in rate or rhythm after intravenous injection (Fig. 3) . As a further evaluation of cardiac toxicity, CPK measurements were perfonned in mice before or after injection with DNA-liposome complexes. No significant changes in CPK levels were noted pre-or postinjection (Table 6 ). In addition to these analyses, histopathological analysis of tissue was performed. No significant pathological abnormalities were detected at 14 days to 6 weeks after injection (Table 5 ). In summary, despite the detection of complexes by PCR within the myocardium, there was no acute or chronic cardiac toxicity from this treatment.
DISCUSSION
The potential of nonviral vectors as a delivery vehicle f human gene therapy has expanded over the past several years. In theory, a variety of such vectors could be employed for gene transfer in vivo, including DNA-liposome complexes, naked plasmid DNA, protein/DNA, or inactivated viral DNA complexes. In this study, we examine the toxicities of a novel DNA-liposome complex that may provide for a substantial increase in the amount of recombinant DNA which could be administered in vivo. In this formulation, the cationic lipid, DMRIE, has been substituted for DC-Chol. The resulting DNA-liposome complex has enhanced transfection efficiencies in vitro (Fig. 1) . Although the magnitude of this effect i s relatively small (two-to seven-fold), these plasmids do not aggregate at higher cell concentrations, and a substantially higher quantity of plasmid can be introduced in vivo by this method. This DNA-liposome also has the ability to facilitate an antitumor response in a case where the other liposome is less active (Fig. 2) .
The ability to introduce genes at higher concentrations could enhance gene transfer and stimulate increased synthesis of gene products that are required for therapeutic effects. For example, recently, high-level concentrations of Lipofectin (BRL, Gaithersburg, MD) and plasmid expression vectors have been described that allow for gene expression systemically following intravenous infection (Zhu et al., 1993) . Additional Phase I studies will be required in humans to test this possibility. This Serum samples were obtained from BALB/c female mice prior to intravenous injection and 16 hr following injecdon of HLA-B7 liposome complexes (n = 5, each dose). Serum was analyzed by Roche Biomedical Laboratory (Buriington, NC). study, together with previous studies that have demonstrated the relative safety of other DNA-liposome complexes Stewart et al., 1992) , provides evidence that the administration of such compounds in vivo i s well tolerated.
The present study confirms that this treatment is tolerated at doses up to 1,000-fold higher than previously analyzed and has the potential to deliver larger quantities of genes. As in previous studies, although DNA was detected in the myocardium following intravenous injection, there was no effect on myocardial function, either acutely or chronically. Therefore, the intravenous infusion of DNA-liposome complexes continues to appear safe with regard to cardiac function even at higher doses. Finally, the concern was raised regarding the potential for inadvertent introduction of DNA into germ cells. We found that DNA was not detected in gonadal tissue, following gene transfer with DNA/DC-Chol complexes, even by PCR (Nabel etal., 1992a) . The previous study used lower doses of the DNAliposome complex. The present study also confirms that the lack of recombinant DNA in gonadal tissue at concentrations up to 1,000-fold greater than those reported previously. Taken together, these data suggest that several cationic lipids may be useful for human gene therapy and are unlikely to cause significant toxicity at these doses, even when modifications are made in one ofthe charged lipid components. These data also suggest that additional modifications of the lipid can be incorporated in the future that will facilitate the efficiency of targeting DNAliposome complexes to specific tissues in vivo.
